Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.40 |
| ▸ | F2 | P00734 | 6/20 | 0.40 |
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 6/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281920 | 0.85 | F10 (0.40) | F10F2PLAUPLGPLAT | |
| SCHEMBL3277202 | 0.80 | LOXL2 (0.43) | PLAULOXLOXL2 | |
| SCHEMBL3276870 | 0.78 | MAOB (0.50) | PLAULOXL2 | |
| SCHEMBL3276867 | 0.78 | IRAK4 (0.39) | F10F2PSEN1PSEN2APH1B | |
| SCHEMBL5318385 | 0.73 | ALDH1A1 (0.46) | LOXLOXL2 | |
| SCHEMBL3278992 | 0.71 | HDAC1 (0.44) | LOXLOXL2 | |
| SCHEMBL3279407 | 0.71 | F2 (0.54) | F10F2 | |
| SCHEMBL5317905 | 0.70 | P2RX3 (0.45) | LOXLOXL2 | |
| SCHEMBL3278982 | 0.70 | CTSS (0.40) | — | |
| SCHEMBL3281929 | 0.70 | F2 (0.58) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700605-B2 | 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | claimed |
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | FLOHR STEFANIE | 2008-09-04 | — | — | US | claimed |
| EP-1907368-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| WO-2007009715-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | claimed |
| US-7700605-B2 | 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | FLOHR STEFANIE | 2008-09-04 | — | — | US | disclosed |
| EP-1907368-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009715-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | USP2, UCHL3, UCHL5 | F10 2607/4885F2 486/4885PLAU 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.